Abstracts tagged "SLE"

Abstract Number: 647 • 2019 ACR/ARP Annual Meeting
Is ANA-status at Disease Inception Associated with Long-term Damage Accrual and Direct and Indirect Health Care Costs in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort?
May Choi¹, Megan Barber ², Marvin Fritzler ¹, John G Hanly ³, Murray Urowitz ⁴, Yvan St-Pierre ⁵, Juanita Romero-Diaz ⁶, Caroline Gordon ⁷, Sang-Cheol Bae ⁸, Sasha Bernatsky ⁹, Daniel J Wallace ¹⁰, David A Isenberg ¹¹, Anisur Rahman ¹², Ellen M Ginzler ¹³, Michelle Petri ¹⁴, Ian Bruce ¹⁵, Paul Fortin ¹⁶, Dafna Gladman ¹⁷, Jorge Sanchez-Guerrero ¹⁸, Rosalind Ramsey-Goldman ¹⁹, Munther A Khamashta ²⁰, Cynthia Aranow ²¹, Meggan Mackay ²², Graciela Alarcón ²³, Susan Manzi ²⁴, Ola Nived ²⁵, Andreas Jönsen ²⁵, Asad Zoma ²⁶, Ronald van Vollenhoven ²⁷, Manuel Ramos-Casals ²⁸, Guillermo Ruiz-Irastorza ²⁹, S Sam Lim ³⁰, Kenneth C Kalunian ³¹, Murat Inanc ³², Diane Kamen ³³, Christine Peschken ³⁴, Soren Jacobsen ³⁵, Anca Askanase ³⁶, Vernon Farewell ³⁷ and Ann E Clarke ³⁸, ¹Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ²University of Calgary, Calgary, Canada, ³Dalhousie University, Halifax, NS, Canada, ⁴University Health Network, University of Toronto, Toronto, ON, Canada, ⁵McGill University Health Centre, Montreal, QC, Canada, ⁶Instituto Nacional de Ciencias Medicas y Nutricion Salvador, Zubiran Vasco de Quiroga, Mexico City, Mexico, ⁷University of Birmingham, Birmingham, United Kingdom, ⁸Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ⁹Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ¹⁰Cedars-Sinai Medical Centre, Beverly Hills, CA, ¹¹Centre for Rheumatology, London, United Kingdom, ¹²University College London, London, United Kingdom, ¹³State University of New York Downstate Medical Center, Brooklyn, NY, ¹⁴Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁵University of Manchester, Manchester, United Kingdom, Manchester, England, United Kingdom, ¹⁶Division de Rhumatologie, Département de Médecine, CHU de Québec – Université Laval, Axe maladies infectieuses et inflammatoires, Centre de recherche du CHU de Québec – Université Laval, Canada, Quebec, QC, Canada, ¹⁷University of Toronto, Toronto, ON, Canada, ¹⁸Toronto Western Hospital, Toronto, ON, Canada, ¹⁹Northwestern University, Chicago, IL, ²⁰King's College London School of Medicine, London, United Kingdom, ²¹Feinstein Institute for Medical Research, Manhasset, NY, ²²Feinstein Institute for Medical Research, New York, ²³University of Alabama at Birmingham, Birmingham, ²⁴Allegheny Health Network, Pittsburg, PA, ²⁵Lund University, Lund, Sweden, ²⁶Hairmyres Hospital, East Kilbride, United Kingdom, ²⁷Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, the Netherlands, Amsterdam, Netherlands, ²⁸Josep Font Autoimmune Diseases Laboratory, Barcelona, Spain, ²⁹Autoimmune Diseases Unit, Hospital Universitario Cruces, Barakaldo, Spain, Barakaldo, Spain, ³⁰Emory University, Atlanta, GA, ³¹UC San Diego School of Medicine, LaJolla, CA, ³²Istanbul University, Istanbul, Turkey, ³³Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA., Charleston, SC, ³⁴University of Manitoba, Winnipeg, Canada, ³⁵Copenhagen Lupus and Vasculitis Clinic, Copenhagen, Denmark, ³⁶Columbia University Medical Center, New York, NY, ³⁷University of Cambridge, Cambridge, United Kingdom, ³⁸University of Calgary, Calgary, AB, Canada
Background/Purpose: We reported that 7.7% (88/1137) of patients in an international inception cohort were ANA-negative at enrolment (Arthritis Care Res 2018 doi:1002/acr23712). There are no…
Abstract Number: 857 • 2019 ACR/ARP Annual Meeting
Mesenchymal Stem Cell Therapy Induces FLT3L and CD1c+ Dendritic Cells in Systemic Lupus Erythematosus Patients
Xinran Yuan ¹, Dandan Wang ¹ and Lingyun Sun², ¹Department of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China (People's Republic), ²The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China (People's Republic)
Background/Purpose: Allogeneic mesenchymal stem cells (MSCs) exhibit immunoregulatory function in human autoimmune diseases such as systemic lupus erythematosus (SLE), but the underlying mechanisms remain incompletely…
Abstract Number: 1200 • 2019 ACR/ARP Annual Meeting
Influenza Vaccination Rates Among Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis on Immunosuppressive Therapy: Findings from a Large Public Hospital
Judith Aniekwena¹, Titilope Olanipekun ² and Valery Effoe ², ¹Morehouse School of Medicine, Atlanta, GA, ²Morehouse School of Medicine, Atlanta
Background/Purpose: Influenza infection constitutes a significant cause of morbidity and mortality in patients living with Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis (RA). The risk…
Abstract Number: 1787 • 2019 ACR/ARP Annual Meeting
The Glucocorticoid-Induced Protein GILZ Represent a Checkpoint in the IFN Program in SLE
Eric Morand¹, Champa Nataraja ¹, Melissa Northcott ¹, Wendy Dankers ¹, Jacqueline Flynn ¹, Wendy Zhu ¹, Taylah Bennett ¹, Mehnaz Pervin ¹, Brendan Russ ¹, James Harris ¹ and Sarah Jones ¹, ¹Monash University, Melbourne, Victoria, Australia
Background/Purpose: Given the primacy of Type I interferon (IFN) pathways in SLE pathogenesis, and the near-ubiquity of glucocorticoid (GC) use in SLE treatment, clarifying the…
Abstract Number: 2540 • 2019 ACR/ARP Annual Meeting
Impact of IL34, IFN-α and IFN-λ1 on Disease Activity of SLE Patients in Egypt
Yasmin Hussein¹ and Yousra Sadeq ¹, ¹Mansoura University Hospital, Mansoura, Egypt
Background/Purpose: SLE is a systemic inflammatory and autoimmune disease. IL-34 plays pivotal roles in the proliferation and differentiation of mononuclear phagocyte cells, osteoclastogenesis and inflammation.…
Abstract Number: 649 • 2019 ACR/ARP Annual Meeting
Potentially Reversible Associations with Fatigue in SLE Patients – Results from a Single-centre Study
Christina Duesing¹, Gamal Chehab ², Jutta Richter ³, Oliver Sander ⁴, Rebecca Fischer-Betz ⁵, Benedikt Ostendorf ¹, Hasan Acar ¹, Ralph Brinks ⁶ and Matthias Schneider ⁵, ¹Policlinic of Rheumatology and Hiller Research Unit Rheumatology, Heinrich-Heine-University, Duesseldorf, Germany, Duesseldorf, Nordrhein-Westfalen, Germany, ²Policlinic of Rheumatology and Hiller Research Unit Rheumatology, Heinrich-Heine-University, Duesseldorf, Germany, ³Department and Hiller Research Unit of Rheumatology, Heinrich-Heine University Duesseldorf, Duesseldorf, Nordrhein-Westfalen, Germany, ⁴Department and Hiller Research Unit of Rheumatology, Heinrich-Heine University Duesseldorf, Duesseldorf, ⁵Policlinic for Rheumatology & Hiller Research Centre for Rheumatology, Heinrich-Heine-University Duesseldorf, Düsseldorf, Germany, ⁶Policlinic for Rheumatology & Hiller Research Centre for Rheumatology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany
Background/Purpose: Fatigue is the most common symptom in SLE patients with a strong impact on patients’ reported quality of life. The cause of fatigue is…
Abstract Number: 884 • 2019 ACR/ARP Annual Meeting
Interferon-Alpha Disrupts Multiple B Cell Tolerance Mechanisms in 3H9 Mice
Dario Ferri ¹, Yuriy Baglaenko ², Kieran Manion ³, Carolina Munoz-Grajales ⁴ and Joan Wither⁵, ¹University Health Network, Toronto, ON, Canada, ²Brigham Woman's Hospital, Boston, ³Krembil Research Institute, Toronto, ON, Canada, ⁴University Health Network, Toronto, Canada, ⁵University Health Network, Krembil Research Institute, Toronto, ON, Canada
Background/Purpose: Interferon-alpha (IFNα) is elevated in Systemic Lupus Erythematosus (SLE) and is thought to play a central role in its pathogenesis. Amongst IFNα’s many effects…
Abstract Number: 1560 • 2019 ACR/ARP Annual Meeting
Imbalance Between Th17 and Regulatory T Cells in Patients with Systemic Lupus Erythematosus Combined EBV/CMV Viremia
Rui Su¹, Yue Liu ¹, Xinyu Zheng ¹, Xiao-feng Li ² and Cai-hong Wang ³, ¹Department of Rheumatology, the Second Hospital of Shanxi Medical University, Taiyuan , Shanxi, China, Tai Yuan, China (People's Republic), ²Department of Rheumatology, the Second Hospital of Shanxi Medical University, Taiyuan , Shanxi, China, TaiYuan, China (People's Republic), ³The Second Hospital of Shanxi Medical University, Tai Yuan, China (People's Republic)
Background/Purpose: Infection is common and is one of the leading causes of morbidity and mortality in Systemic Lupus Erythematosus (SLE) patients . Excessive using glucocorticoid…
Abstract Number: 1829 • 2019 ACR/ARP Annual Meeting
Ability of Inflammatory and Regulatory Soluble Mediators to Forecast Impending Clinical Disease Flare and Inform a Refined Lupus Flare Prediction Index in a Confirmatory Cohort of SLE Patients
Melissa E. Munroe¹, Sarah Kleckner ¹, Wade DeJager ¹, Susan R. Macwana ¹, Joel Guthridge ², Eldon Jupe ³, Mohan Purushothaman ³, Sanjiv Sharma ³, Nancy Redinger ¹, Teresa Aberle ¹, Stan Kamp ¹, Cristina Arriens ², Eliza F. Chakravarty ², Joan T. Merrill ⁴ and Judith James ², ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³Progentec Diagnostics, Inc., Oklahoma City, OK, ⁴Okalahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: SLE is marked by altered immune regulation linked to waxing and waning clinical disease activity. This study seeks to verify the alteration of inflammatory…
Abstract Number: 2547 • 2019 ACR/ARP Annual Meeting
Safety Results of 50% Enrollment from a Multicenter, Randomized, Double‑blind, Placebo‑controlled Study to Assess the Efficacy and Safety of Repository Corticotropin Injection in Patients with Systemic Lupus Erythematosus Despite Moderate‑dose Corticosteroid Use
Anca Askanase¹, Dharani Munirathinam ², Enxu Zhao ², Julie Zhu ², Erin Connolly-Strong ² and Richard Furie ³, ¹Columbia University Medical Center, New York, NY, ²Mallinckrodt Pharmaceuticals, ARD, LLC, Bedminster, NJ, ³Northwell Health, Great Neck, NY
Background/Purpose: Repository corticotropin injection (RCI) is a naturally sourced complex mixture of adrenocorticotropic hormone (ACTH1-39) analogues and other pituitary peptides that stimulates endogenous corticosteroid (CS)…
Abstract Number: 658 • 2019 ACR/ARP Annual Meeting
Disentangling Connective Tissue Diseases: Overlaps and Disparities in Clinical Diagnosis, Classification Criteria and Autoantibodies – Results from the Lupus Extended Autoimmune Phenotype Study
Sarah Dyball¹, John Reynolds ², Hector Chinoy ², Tracy Briggs ², Sahena Haque ³, Eoghan McCarthy ⁴, Ellen Bruce ⁵, Ariane Herrick ⁶, Ian Bruce ⁷ and Ben Parker ⁸, ¹University of Manchester, Manchestser, United Kingdom, ²University of Manchester, Manchester, United Kingdom, ³University Hospital South Manchester, Manchester, United Kingdom, ⁴Manchester University NHS FT, Manchester Academic Health Science Centre, Manchester, United Kingdom, Manchester, England, United Kingdom, ⁵Central Manchester University Hospitals, Manchester, United Kingdom, ⁶Salford Royal Foundation Trust, Manchester, United Kingdom, ⁷University of Manchester, Manchester, United Kingdom, Manchester, England, United Kingdom, ⁸University of Manchester, NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom; Manchester University NHS FT, Manchester Academic Health Science Centre, Manchester, United Kingdom, Manchester, United Kingdom
Background/Purpose: Connective tissue diseases (CTDs) are a heterogeneous group of diseases with overlapping clinical features and shared immunopathology. In routine practice, a clinician diagnosis is…
Abstract Number: 897 • 2019 ACR/ARP Annual Meeting
Mortality Rates After Coronary Revascularization Procedures Among Systemic Lupus Erythematosus Compared to Diabetes Mellitus and General Population Medicaid Patients
Medha Barbhaiya¹, Sarah Chen ², Candace Feldman ³, Hongshu Guan ³, Brendan Everett ⁴ and Karen Costenbader ⁴, ¹Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ²Brigham and Women's Hospital and Harvard Medical School, Boston, ³Brigham and Women's Hospital, Boston, ⁴Brigham and Women's Hospital, Boston, MA
Background/Purpose: Despite similar myocardial infarction risks in SLE and diabetes mellitus (DM) patients, individuals with SLE enrolled in Medicaid had substantially higher rates of coronary…
Abstract Number: 1571 • 2019 ACR/ARP Annual Meeting
Validity Evidence Supports the Use of Automated Neuropsychological Assessment Metrics (ANAM) as a Screening Tool for Cognitive Impairment in Patients with Systemic Lupus Erythematosus
Oshrat Tayer-Shifman¹, Robin Green ², Dorcas Beaton ³, Lesley Ruttan ², Joan Wither ⁴, Maria Tartaglia ⁵, Mahta Kakvan ¹, Sabrina Lombardi ², Nicole Anderson ¹, Jiandong Su ¹, Dennisse Bonilla ¹, Moe Zandy ¹, May Choi ⁶, Marvin Fritzler ⁶ and Zahi Touma ⁷, ¹University Health Network, University of Toronto, Toronto, ON, Canada, ²University Health Network, Toronto, ON, Canada, ³St. Michael's Hospital, Toronto, ON, Canada, ⁴University Health Network, Krembil Research Institute, Toronto, ON, Canada, ⁵University Health Network, University of Toronto, Toronto, ON, Canada, ⁶Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁷University Health Network, University of Toronto, Toronto, Canada
Background/Purpose: Cognitive impairment (CI) is highly prevalent in Systemic Lupus Erythematosus (SLE). Screening for CI in SLE may be delayed, if relying on the American…
Abstract Number: 1844 • 2019 ACR/ARP Annual Meeting
The Contribution of Disease Activity, Depression, and Anxiety to Health-Related and Non-Health-Related Quality of Life in US and Filipino Patients with SLE
Alexandra Watts¹, Desiree Azizoddin ², Shadi Gholizadeh ³, Sarah Mills ⁴, Geraldine Zamora ⁵, Daniel Wallace ⁶, Meenakshi Jolly ⁷, Michael Weisman ⁸ and Perry Nicassio ⁹, ¹University of California, Los Angeles, Los Angeles, CA, ²Dana-Farber Cancer Institute, Boston, MA, ³McGill University, Montreal, Canada, ⁴Lineberger Comprehensive Cancer Center, Chapel Hill, NC, ⁵Manila Doctors Hospital, Manila, Philippines, ⁶Cedars-Sinai Medical Center/University California at Los Angeles, Los Angeles, CA, ⁷Rush University Medical Center, Chicago, IL, ⁸David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁹David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: It is well known that patients with SLE are often afflicted with deficits in quality of life and problems with physical impairment and psychosocial…
Abstract Number: 2549 • 2019 ACR/ARP Annual Meeting
Population Pharmacokinetics of Atacicept in Systemic Lupus Erythematosus (SLE) – an Analysis of Three Clinical Trials
Maria Pitsui ¹, Orestis Papasouliotis², Colm Farrell ¹, Pascal Girard ², Oezkan Yalkinoglu ³ and Cristina Vazquez-Mateo ⁴, ¹ICON Plc, Dublin, Ireland, ²Merck Institute for Pharmacometrics, Lausanne, Switzerland, ³Merck KGaA, Darmstadt, Germany, ⁴EMD Serono Research and Development Institute, Inc., Billerica, MA
Background/Purpose: Atacicept targets the B-cell stimulating factors BLyS and APRIL and has been shown to reduce SLE disease activity. The aim of the analysis was…

1
2
3
…
38
Next Page »